ChemoTech and ABEX ready to start the study in Malaysia
Abex Medical System Sdn. Bhd. ('ABEX') and University Hospital Pusat Perubatan Universiti Malaya ('PPUM') in Kuala Lumpur have now passed all administrative barriers to start the case study approved by the Ministry of Health and Ethical Committee earlier this year.
As previously announced, the study will initially include a small number of patients under the ‘special access program’, that PPUM received approval for earlier this year. The first patient is scheduled to start treatment in three weeks.
I’m very delighted to inform the market that we are following the schedule that we set up with ABEX at the beginning of the year. That we now through this "Companionate Use program" can make IQwave™ and our D-EECT treatment available for cancer patients in Malaysia, until the CE-mark and the registration is ready, is extremely pleasing, says Mohan Frick, CEO at ChemoTech.
Everyone is excited and can’t wait to have this trial as soon as possible. We have been following this site for almost half a year and in between we faced a lot of obstacles. We are glad that we finally made it by having the special access from our local Authority and with the approval of the Ethical Committee, says Jess Ooi, Product Manager at ABEX.
For more information, please contact:
Mohan Frick, CEO
+46 (0)10-218 93 00
This information is such information which Scandinavian ChemoTech AB (publ) are obligated to make public according to EU’s market abuse regulation. The information was submitted by the agency of above stated contact person, to be made public on Friday 31st of August 2018 at 10.10 (CET).
Scandinavian ChemoTech AB (publ)
ChemoTech is a young and dynamic life science company that possesses a great medical expertise and technical knowledge. Our latest launch of IQWave™ is an innovation within electrochemotherapy, that is adapted for the treatment of different types of tumors. ChemoTech strives to contribute to a more accessible cancer care. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North in Stockholm and Västra Hamnen Corporate Finance AB is the company's Certified Adviser. The company is headquartered in Malmö, in the midst of the medical technology expansionary Öresund region.